Segall Bryant & Hamill LLC Decreases Stock Position in LeMaitre Vascular, Inc. $LMAT

Segall Bryant & Hamill LLC trimmed its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 34.9% during the first quarter, Holdings Channel.com reports. The fund owned 52,252 shares of the medical instruments supplier’s stock after selling 27,990 shares during the period. Segall Bryant & Hamill LLC’s holdings in LeMaitre Vascular were worth $5,704,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. M&T Bank Corp lifted its holdings in shares of LeMaitre Vascular by 2,240.5% in the fourth quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock valued at $32,283,000 after purchasing an additional 381,061 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of LeMaitre Vascular by 144.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock worth $31,731,000 after purchasing an additional 231,157 shares in the last quarter. Bessemer Group Inc. raised its position in shares of LeMaitre Vascular by 292.3% during the 1st quarter. Bessemer Group Inc. now owns 171,838 shares of the medical instruments supplier’s stock worth $18,759,000 after purchasing an additional 128,033 shares during the last quarter. Millennium Management LLC raised its position in shares of LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after purchasing an additional 115,141 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in LeMaitre Vascular by 13.4% in the 4th quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock valued at $76,245,000 after buying an additional 111,193 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Insider Transactions at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,928 shares of LeMaitre Vascular stock in a transaction on Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the completion of the sale, the insider owned 3,749 shares of the company’s stock, valued at $401,143. The trade was a 43.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total value of $560,388.40. Following the completion of the transaction, the director owned 3,942 shares of the company’s stock, valued at $437,956.20. The trade was a 56.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 54,453 shares of company stock worth $5,906,174 over the last quarter. 7.40% of the stock is currently owned by insiders.

LeMaitre Vascular Stock Up 2.3%

Shares of NASDAQ LMAT opened at $103.61 on Tuesday. The firm has a market cap of $2.37 billion, a P/E ratio of 38.23, a price-to-earnings-growth ratio of 2.81 and a beta of 0.52. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. LeMaitre Vascular, Inc. has a 1 year low of $79.39 and a 1 year high of $118.01. The firm’s 50 day moving average price is $97.27 and its 200 day moving average price is $99.90.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The company had revenue of $66.55 million during the quarter, compared to the consensus estimate of $66.67 million. During the same period in the previous year, the firm posted $0.48 EPS. LeMaitre Vascular’s revenue was up 11.1% on a year-over-year basis. As a group, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on LMAT. Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday. Barrington Research restated an “outperform” rating and issued a $120.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday, June 3rd. Weiss Ratings lowered LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, June 30th. Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Wells Fargo & Company lifted their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $112.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.